82 results
424B7
fc2 7tj0id1qnqrin
10 Jan 24
Prospectus with selling stockholder info
9:22am
8-K
EX-10.1
89h7zasikz794t9cm
8 Jan 24
Entry into a Material Definitive Agreement
7:05am
424B7
lonob
16 Nov 23
Prospectus with selling stockholder info
4:16pm
8-K
y5a2b
12 Oct 23
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
4:13pm
8-K
EX-99.2
w8ar6bjg
12 Oct 23
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
4:13pm
8-K
EX-99.1
if4s5691va6o 7wbcl
12 Oct 23
Relay Therapeutics Announces Initial RLY-4008 (lirafugratinib) Data Demonstrating Durable Responses Across Multiple FGFR2-Altered Solid Tumors
4:13pm
8-K
EX-99.1
kf9tb 06ija116g9
25 May 23
Relay Therapeutics Announces Full Dose Escalation Data for RLY-4008
5:05pm
424B5
bunob858w io03a
13 Sep 22
Prospectus supplement for primary offering
5:19pm
424B5
6v3p16b 8dn
12 Sep 22
Prospectus supplement for primary offering
7:35am
8-K
EX-99.2
kh1vz8pw9b
12 Sep 22
Enrollment for the pivotal cohort anticipated to be completed in the second half of 2023
6:05am